Document 0101
 DOCN  M9620101
 TI    Immunogenicity of the yeast recombinant p17/p24:Ty virus-like particles
       (p24-VLP) in healthy volunteers.
 DT    9602
 AU    Weber J; Cheinsong-Popov R; Callow D; Adams S; Patou G; Hodgkin K;
       Martin S; Gotch F; Kingsman A; St Mary's Hospital Medical School,
       London, UK.
 SO    Vaccine. 1995 Jun;13(9):831-4. Unique Identifier : AIDSLINE MED/96066231
 AB    In this Phase I study, immunisation with the yeast-derived p24
       virus-like particles Ty p24-VLP (3 x 100 or 3 x 500 micrograms
       subcutaneously) in 16 healthy male subjects elicited p24 antibody
       responses in 4 of 16 (25%) subjects. After a fourth, intramuscular,
       immunisation (500 micrograms), p24 antibody responses were detected in
       11 of 15 (70%) subjects. In addition to p24 antibody responses, T cell
       proliferative responses were also observed, although no HLA restricted
       p24-specific cytotoxic T cell responses were detected. The results
       demonstrate that Ty p24-VLP is immunogenic and well-tolerated in healthy
       male subjects.
 DE    Adult  AIDS Vaccines/GENETICS/*IMMUNOLOGY/THERAPEUTIC USE  Blotting,
       Western  Enzyme-Linked Immunosorbent Assay  Gene Products,
       gag/*IMMUNOLOGY  Human  HIV/*IMMUNOLOGY  HIV Antibodies/BIOSYNTHESIS
       HIV Antigens/*IMMUNOLOGY  HIV Core Protein
       p24/GENETICS/*IMMUNOLOGY/THERAPEUTIC USE  HIV Infections/*PREVENTION &
       CONTROL  Male  Middle Age  Reference Values  Saccharomyces
       cerevisiae/GENETICS  T-Lymphocytes, Cytotoxic/CYTOLOGY/IMMUNOLOGY
       Vaccines, Synthetic/GENETICS/IMMUNOLOGY/THERAPEUTIC USE  CLINICAL TRIAL
       CLINICAL TRIAL, PHASE I  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).